Exploring Ugi-Azide Four-Component Reaction Products for Broad-Spectrum Influenza Antivirals with a High Genetic Barrier to Drug Resistance
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2045-2322
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Exploring Ugi-Azide Four-Component Reaction Products for Broad-Spectrum Influenza Antivirals with a High Genetic Barrier to Drug Resistance ; volume:8 ; number:1 ; day:15 ; month:3 ; year:2018 ; pages:1-14 ; date:12.2018
Scientific reports ; 8, Heft 1 (15.3.2018), 1-14, 12.2018
- Klassifikation
-
Medizin, Gesundheit
- Urheber
-
Zhang, Jiantao
- Beteiligte Personen und Organisationen
-
Hu, Yanmei
Foley, Christopher
Wang, Yuanxiang
Musharrafieh, Rami
Xu, Shuting
Zhang, Yongtao
Ma, Chunlong
Hulme, Christopher
Wang, Jun
SpringerLink (Online service)
- DOI
-
10.1038/s41598-018-22875-9
- URN
-
urn:nbn:de:1111-201805145222
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:48 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Zhang, Jiantao
- Hu, Yanmei
- Foley, Christopher
- Wang, Yuanxiang
- Musharrafieh, Rami
- Xu, Shuting
- Zhang, Yongtao
- Ma, Chunlong
- Hulme, Christopher
- Wang, Jun
- SpringerLink (Online service)
Ähnliche Objekte (12)
Advanced molecular tweezers as broad-spectrum antivirals
Expanding horizons of iminosugars as broad-spectrum anti-virals: mechanism, efficacy and novel developments
A painful lesson from the COVID-19 pandemic: the need for broad-spectrum, host-directed antivirals
Macromolecular viral entry inhibitors as broad-spectrum first-line antivirals with activity against SARS-CoV-2
Macromolecular Viral Entry Inhibitors as Broad‐Spectrum First‐Line Antivirals with Activity against SARS‐CoV‐2
Enantioselective Ugi and Ugi-azide reactions catalyzed by anionic stereogenic-at-cobalt(III) complexes
Broad-spectrum inflammasome inhibition by thiomuscimol
Two genomic regions of a sodium azide induced rice mutant confer broad-spectrum and durable resistance to blast disease
Novel and potent inhibitors targeting DHODH are broad-spectrum antivirals against RNA viruses including newly-emerged coronavirus SARS-CoV-2
Synthetic optimization of cystobactamids as broad-spectrum antibiotics
Novel quinoline derivatives with broad‐spectrum antiprotozoal activities
Correction to: Novel and potent inhibitors targeting DHODH are broad-spectrum antivirals against RNA viruses including newly-emerged coronavirus SARS-CoV-2
Advanced molecular tweezers as broad-spectrum antivirals
Expanding horizons of iminosugars as broad-spectrum anti-virals: mechanism, efficacy and novel developments
A painful lesson from the COVID-19 pandemic: the need for broad-spectrum, host-directed antivirals
Macromolecular viral entry inhibitors as broad-spectrum first-line antivirals with activity against SARS-CoV-2
Macromolecular Viral Entry Inhibitors as Broad‐Spectrum First‐Line Antivirals with Activity against SARS‐CoV‐2
Enantioselective Ugi and Ugi-azide reactions catalyzed by anionic stereogenic-at-cobalt(III) complexes
Broad-spectrum inflammasome inhibition by thiomuscimol
Two genomic regions of a sodium azide induced rice mutant confer broad-spectrum and durable resistance to blast disease
Novel and potent inhibitors targeting DHODH are broad-spectrum antivirals against RNA viruses including newly-emerged coronavirus SARS-CoV-2
Synthetic optimization of cystobactamids as broad-spectrum antibiotics
Novel quinoline derivatives with broad‐spectrum antiprotozoal activities
Correction to: Novel and potent inhibitors targeting DHODH are broad-spectrum antivirals against RNA viruses including newly-emerged coronavirus SARS-CoV-2
Advanced molecular tweezers as broad-spectrum antivirals
Expanding horizons of iminosugars as broad-spectrum anti-virals: mechanism, efficacy and novel developments
A painful lesson from the COVID-19 pandemic: the need for broad-spectrum, host-directed antivirals
Macromolecular viral entry inhibitors as broad-spectrum first-line antivirals with activity against SARS-CoV-2
Macromolecular Viral Entry Inhibitors as Broad‐Spectrum First‐Line Antivirals with Activity against SARS‐CoV‐2
Enantioselective Ugi and Ugi-azide reactions catalyzed by anionic stereogenic-at-cobalt(III) complexes
Broad-spectrum inflammasome inhibition by thiomuscimol
Two genomic regions of a sodium azide induced rice mutant confer broad-spectrum and durable resistance to blast disease
Novel and potent inhibitors targeting DHODH are broad-spectrum antivirals against RNA viruses including newly-emerged coronavirus SARS-CoV-2
Synthetic optimization of cystobactamids as broad-spectrum antibiotics
Novel quinoline derivatives with broad‐spectrum antiprotozoal activities